DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE
Pre-Launchdapagliflozin and metformin hydrochloride
ANDAORALTABLET
Approved
Apr 2026
Lifecycle
Pre-Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (dapagliflozin and metformin hydrochloride) by Aurobindo Pharma is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2026.
Drug data last refreshed 18h ago
Mechanism of Action
Sodium-Glucose Transporter 2 Inhibitors
Pharmacologic Class:
Sodium-Glucose Cotransporter 2 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.